Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma

(MedPage Today) -- The FDA granted accelerated approval to sonrotoclax (Beqalzi) as the first BCL2 inhibitor for relapsed or refractory mantle cell lymphoma (MCL), a rare and often aggressive subtype of non-Hodgkin lymphoma. A next-generation...
Source
MedPage Today
Opens original article in a new tab



